

Material Information (3176 MEDIGEN)

SEQ_NO	1	Date of announcement	2026/04/04	Time of announcement	20:00:13
Subject	OBP-301, a new drug underdevelopment, has completed a Conformity Audit and On-site Inspection				
Date of events	2026/04/03	To which item it meets	paragraph 53		

Statement

- 1.Date of occurrence of the event:2026/04/03
- 2.Company name:Medigen Biotechnology Corp.
- 3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office
- 4.Reciprocal shareholding ratios:N/A
- 5.Cause of occurrence:
Medigen Biotechnology Corp. and the Japanese publicly traded company Oncolys BioPharma("Oncolys", TSE stock code 4588), are jointly developing the oncolytic virus new drug OBP-301 (Telomelysin). Oncolys announced on April 3, 2026, that following the submission of a New Drug Application to Japan's PMDA in December 2025, OBP-301 has completed a Conformity Audit and a GCP On-site Inspection. The company has received a notification from the PMDA indicating that the results of both procedures were determined to be compliant. This confirms that the overall reliability of the data-from original data to the submitted application dossier-has been verified.
- 6.Countermeasures:none
- 7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
 - (1)This announcement provides an update and additional explanations following the progress of the NDA submission for OBP-301 announced on December 15, 2025.
 - (2)The development timeline for new drugs is long, requires substantial investment, and does not guarantee success. These factors may pose risks to investors, who are advised to exercise prudent judgment before making investment decisions.
 - (3)Our company and Oncolys in Japan jointly share the development costs of OBP-301 and will share the future commercial benefits.
 - (4)Link to the announcement by Oncolys, Japan:
<https://ssl4.eir-parts.net/doc/4588/tdnet/2786662/00.pdf>